---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-029349"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:17:07.012999+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Contineum reports positive Phase 1b PET data for PIPE-791; confirms target engagement

## Summary
- PIPE-791 achieved high LPA1 brain receptor occupancy in healthy volunteers and PrMS patients.
- Plasma EC50 of 37 ng/mL at 24h and 12 ng/mL at 168h shows sustained target engagement.
- Safety profile consistent with prior studies; no new safety signals identified.
- Planned Phase 2 doses expected to exceed 90% target coverage at trough with once-daily dosing.
- 12 healthy volunteers and 4 PrMS patients enrolled; trial met primary PK/RO correlation objectives.

## SEC filing metadata
- accession: 0001437749-25-029349
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774925029349/0001437749-25-029349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774925029349/ctnm20250910_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-029349
- JSON: https://secwatch.observer/filing/0001437749-25-029349.json
- Plain text: https://secwatch.observer/filing/0001437749-25-029349.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.